ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
During the Aβ targeting therapies symposium at this month's International Virtual Conference on Alzheimer’s Disease and Parkinson’s Disease (AD/PD 2021),…
Last week, hot on the heels of an FDA emergency use authorisation (EUA), Johnson & Johnson (J&J) subsidiary Janssen’s Covid-19…
The World Health Organization declared the Covid-19 crisis to be a pandemic in mid-March 2020. Nine months later, three vaccines…
Despite the theoretical potential of inactivated virus vaccines to offer a lead over other Covid-19 vaccine technologies against variants of…
Long-term Covid-19 vaccine durability has become less of an endgame since it has become increasingly likely additional shots will be…
Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due…
With Johnson & Johnson (J&J) and Novavax, two more companies presented Covid-19 vaccine efficacy data last week. With an efficacy…
There are now more than 95 million confirmed cases of Covid-19 worldwide. The disease has reached 193 countries, with the…
Regeneron Pharmaceuticals has reported positive initial results from an ongoing Phase III clinical trial of antibody cocktail REGEN-COV used as…